adalimumab Articles
In Japan, Mitsubishi Tanabe files for canagliflozin approval; Eisai/AbbVie's Humira gets new indication
28 May 2013
US gastroenterologists increasingly using biologics to treat Crohn's patients in remission
6 March 2013
FDA accepts file for new Actemra formulation in rheumatoid arthritis
28 February 2013
Positive Ph III results for AbbVie's Humira in pediatric Crohn's disease; five leukemia studies suspended
17 February 2013
Steady sales for MAbs in rheumatoid arthritis - can biologics beat the patent cliff?
13 February 2013
Global rheumatology market controlled by Enbrel, Humira and Remicade
24 December 2012
Biosimilars threaten to burst Humira's blockbuster bubble
29 November 2012
EU Commission approves Bayer's Eylea for wet AMD and Abbott's Humira for pediatric Crohn's
28 November 2012
Abbott presents new Humira data at ACR
12 November 2012
AET BioTech and BioXpress to co-develop biosimilar Humira
2 November 2012
Good news from CHMP for Astellas, Savient, Bayer and Abbott, but not for Lundbeck and Merz
22 October 2012
Abbott's Humira gets FDA backing for new use
30 September 2012
Uptake of biosimilars will see Remicade and Humira sales decline in 2017
26 September 2012
US gastroenterologists' attitudes to prescribing for Crohn's disease and ulcerative colitis
9 September 2012
Abbott's Humira cleared for Crohn's disease in EU
31 August 2012
Abbott's Humira gains FDA panel backing for wider use
29 August 2012
EMA advisory backs Humira for UC and expanded use of Byetta
20 February 2012
US gastroenterologists see significant growth for Abbott/Eisai’s Humira in ulcerative colitis once indication is approved
29 November 2011
Remicade, Humira and Enbrel made up 40% of the immunomodulators market in 2010; report
23 August 2011
More Japanese drug OKs: GSK’s Rotarix and Lamictal; Takeda’s Liovel and new use for Eisai/Abbott’s Humira
4 July 2011
Abbott debuts pediatric Humira in UK; gets US FDA appro for first infant-specific dosage for Creon
15 June 2011
Abbott prevails as US Court of Appeals overturns $1.8 billion patent verdict for J&J unit
24 February 2011
New data offer insights into TNF non-responders actively switched to Johnson & Johnson’s Remicade
9 November 2010
Abbott/Eisai's Humira emerges as market leader in psoriatic arthritis, garnering sales of over $500 million in 2009
5 November 2010
US FDA moves approval goalposts for GSK/Valeant’s ezogabine and Eisai’s eribulin; Abbott/Eisai’s Humira filed for additional indication in Japan
1 September 2010
Psoriasis drug market expected to double to $6.8 Billion in 2019, driven by biologics penetration and Interleukin/TNF-alpha inhibitors
10 August 2010
Novel oral drug for Crohn's disease would earn 40% patient share in USA and Europe, says DR report
15 April 2010
Abbott/Eisai’s Humira most favored among biologics for Crohn's disease and ulcerative colitis, says DR report
9 April 2010
Ulcerative colitis drug market will nearly double to $2.1 billion in 2018 in top seven markets
15 February 2010
Increasing competition from other biologics will continue to erode Enbrel's dominance in the psoriasis drug market, DR report concludes
12 February 2010
Abbott Lab’s 4th-quarter 2009 profit flat due to charges, buts sales rise nearly 11% driven by Humira; still open to buys
28 January 2010
UK’s NICE does about turn on UCB’s Cimzia, backing it use for RA, but with cost-sharing deal
21 January 2010
FDA finally approves Roche’s Actemra for moderately-to-severely active rheumatoid arthritis
11 January 2010
Biosimilars of TNF-alpha inhibitors stand to erode over $9 billion in brand sales in USA and Europe by 2018
4 November 2009
UCB’s Cimzia approved for RA in Europe
7 October 2009
Health Canada working to update labeling of TNF blockers
29 August 2009
US FDA says cancer warnings required for TNF blockers
5 August 2009
Eisai returns to profit after MGI acquisition
1 June 2009
Abbott celebrates 20th anniversary of R&D plant
14 May 2009
Strong interest in J&J's Simponi
13 May 2009
53% jump in 1st-qtr profit for Abbott
15 April 2009
Eisai profit down 38% on MGI acquisition
16 February 2009
Abbott's 4th-qtr profit jumps 28% on strong sales of Humira and divestment of spinal products unit
26 January 2009
Bayer sues Abbott for slice of Humira earnings
12 January 2009
Humira shows three year fistula effect
27 October 2008
Abbott's Humira does well in REVEAL trial
29 September 2008
US FDA calls for tougher warnings on TNF-alpha drugs on 240 cases of histoplasmosis
15 September 2008
NICE rejects second-line use of TNF-alpha drugs
28 July 2008
Abbott's 2nd qtr results beat expectations
28 July 2008
Humira launched in Japan for treatment of RA
30 June 2008
Humira recommended for plaque psoriasis
30 June 2008
Japan stock market week to June 23, 2008
30 June 2008
74% of AS patients on Humira have reduced symptoms
23 June 2008
Strong long-term CD data on Humira
2 June 2008
Japan stock market week to Aril 21, 2008
28 April 2008
Abbott reports 35% rise in earnings
28 April 2008
Abbott's Humira approved in Japan
21 April 2008
Humira and Naglazyme recommended for approval in Japan
10 March 2008
Japan stock market week to Mar 3, 2008
10 March 2008
FDA approves Abbott's Humira for JIA
3 March 2008
Fifth indication for Abbott's Humira
28 January 2008
Abbott Labs returns to profit in 4th-qtr 2007
28 January 2008
Humira cleared for plaque psoriasis in EU
7 January 2008
Ph I/II US trial of tgACC94 resumes
3 December 2007
CHMP issues negative view on Cimzia in Crohn's
26 November 2007
"Devastating" AS ruling by the NICE condemned
19 November 2007
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
